CO6300943A2 - Derivados de 2-oxo-aquil-1-piperazin-2-ona su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 2-oxo-aquil-1-piperazin-2-ona su preparacion y su aplicacion en terapeutica

Info

Publication number
CO6300943A2
CO6300943A2 CO10156026A CO10156026A CO6300943A2 CO 6300943 A2 CO6300943 A2 CO 6300943A2 CO 10156026 A CO10156026 A CO 10156026A CO 10156026 A CO10156026 A CO 10156026A CO 6300943 A2 CO6300943 A2 CO 6300943A2
Authority
CO
Colombia
Prior art keywords
piperazin
oxo
therapeutics
preparation
application
Prior art date
Application number
CO10156026A
Other languages
English (en)
Inventor
Marco Baroni
Francoise Bono
Sandrine Delbary-Gossart
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6300943A2 publication Critical patent/CO6300943A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención tiene por objeto derivados de 4-{2-[fenil-3,6-dihidro-piridin-1-iI]-2-oxo-alquil}-1-piperazin-2-ona de 4-{2-[fenil-2,5-dihidro-pirrol-1-il]-2-oxo-alquiI}-1-piperazin-2-ona, de fórmula general (I), en la que A, B, m, R3 y n se definen como en la reivindicación 1, su preparación y su aplicación en terapéutica.
CO10156026A 2008-06-13 2010-12-13 Derivados de 2-oxo-aquil-1-piperazin-2-ona su preparacion y su aplicacion en terapeutica CO6300943A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803298A FR2932481B1 (fr) 2008-06-13 2008-06-13 Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
CO6300943A2 true CO6300943A2 (es) 2011-07-21

Family

ID=40305319

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10156026A CO6300943A2 (es) 2008-06-13 2010-12-13 Derivados de 2-oxo-aquil-1-piperazin-2-ona su preparacion y su aplicacion en terapeutica

Country Status (32)

Country Link
US (2) US8247404B2 (es)
EP (1) EP2310383B8 (es)
JP (1) JP5476372B2 (es)
KR (1) KR101601999B1 (es)
CN (1) CN102124001B (es)
AR (1) AR072102A1 (es)
AT (1) ATE535524T1 (es)
AU (1) AU2009259120B2 (es)
BR (1) BRPI0915482B8 (es)
CA (1) CA2726666C (es)
CL (1) CL2010001432A1 (es)
CO (1) CO6300943A2 (es)
CY (1) CY1112417T1 (es)
DK (1) DK2310383T3 (es)
EA (1) EA019924B1 (es)
ES (1) ES2378380T3 (es)
FR (1) FR2932481B1 (es)
HK (1) HK1158632A1 (es)
HR (1) HRP20120187T1 (es)
IL (1) IL209903A (es)
JO (1) JO2773B1 (es)
MX (1) MX2010013694A (es)
MY (1) MY151228A (es)
NZ (1) NZ589842A (es)
PL (1) PL2310383T3 (es)
PT (1) PT2310383E (es)
RS (1) RS52252B (es)
SI (1) SI2310383T1 (es)
TW (1) TWI400238B (es)
UY (1) UY31894A (es)
WO (1) WO2009150387A1 (es)
ZA (1) ZA201008791B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
EP2950095B1 (en) 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3236243A1 (de) * 1982-09-30 1984-04-05 Merck Patent Gmbh, 6100 Darmstadt Schwefelhaltige indolderivate
FR2744448B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
AU749271B2 (en) * 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1165522A1 (en) 1999-04-06 2002-01-02 Krenitsky Pharmaceuticals, Inc. Neurotrophic thio substituted pyrimidines
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75

Also Published As

Publication number Publication date
BRPI0915482A2 (pt) 2015-11-10
ES2378380T3 (es) 2012-04-11
CL2010001432A1 (es) 2011-05-13
IL209903A (en) 2014-06-30
MY151228A (en) 2014-04-30
JO2773B1 (en) 2014-03-15
PT2310383E (pt) 2012-03-06
JP2011522868A (ja) 2011-08-04
US20110144122A1 (en) 2011-06-16
HRP20120187T1 (hr) 2012-03-31
ZA201008791B (en) 2012-02-29
BRPI0915482B8 (pt) 2021-05-25
EP2310383A1 (fr) 2011-04-20
AR072102A1 (es) 2010-08-04
SI2310383T1 (sl) 2012-03-30
RS52252B (en) 2012-10-31
PL2310383T3 (pl) 2012-04-30
CY1112417T1 (el) 2015-12-09
US20120289518A1 (en) 2012-11-15
CA2726666C (fr) 2016-08-16
EP2310383B1 (fr) 2011-11-30
EA201170015A1 (ru) 2011-06-30
ATE535524T1 (de) 2011-12-15
US8247404B2 (en) 2012-08-21
TW201002686A (en) 2010-01-16
IL209903A0 (en) 2011-02-28
KR101601999B1 (ko) 2016-03-17
CN102124001B (zh) 2014-01-22
KR20110031317A (ko) 2011-03-25
TWI400238B (zh) 2013-07-01
UY31894A (es) 2010-01-29
BRPI0915482B1 (pt) 2020-11-24
AU2009259120A1 (en) 2009-12-17
WO2009150387A1 (fr) 2009-12-17
AU2009259120B2 (en) 2014-01-16
DK2310383T3 (da) 2012-03-26
JP5476372B2 (ja) 2014-04-23
CA2726666A1 (fr) 2009-12-17
EP2310383B8 (fr) 2012-04-11
MX2010013694A (es) 2011-02-23
FR2932481A1 (fr) 2009-12-18
EA019924B1 (ru) 2014-07-30
FR2932481B1 (fr) 2010-10-08
HK1158632A1 (en) 2012-07-20
NZ589842A (en) 2012-12-21
CN102124001A (zh) 2011-07-13

Similar Documents

Publication Publication Date Title
CO6341476A2 (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
ECSP099791A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparación y su aplicación en terapéutica
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
CO6300943A2 (es) Derivados de 2-oxo-aquil-1-piperazin-2-ona su preparacion y su aplicacion en terapeutica
CR20110220A (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
PA8793101A1 (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CR20110246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica.
UY32757A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica
CL2012001010A1 (es) Compuesto 4-[etil(dimetil)amonio]butanoato; procesos de preparacion de este compuesto; y su uso en el tratamiento de enfermedades cardiovasculares.
UY33092A (es) Compuestos de triazol, su uso y agentes que los contienen
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
UY32103A (es) Compuestos de triazol, su uso, así como productos que los contienen
UY32102A (es) Compuestos de triazol, su uso, así como productos que los contienen
UY32101A (es) Compuestos de triazol, su uso, así como productos que los contienen
CR20110527A (es) Derivados de 1-alquil-cinolin-4(1h)-ona, su preparación y su aplicación en terapéutica
ECSP088574A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
CO6501125A2 (es) Nuevos derivados (heterociclico-tetrahidro-piridin)-(piperazinil)-1- alcanona y (heterociclo-dhidro-pirrolidin)-(piperazinil)-1-alcanona y su utilización como inhibidores de p75
UY30085A1 (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion su aplicacion en terapeutica

Legal Events

Date Code Title Description
FG Application granted